Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Impact · against what's priced in

The news is largely noise for ABBV and BMY as the market has already absorbed their respective growth trajectories and patent cliff risks. BMY's dividend remains safe due to a low payout ratio, but the upcoming Eliquis revenue drop reinforces a stagnant outlook.

ABBV+0.00

Already priced in

The price assumes

SKYRIZI and RINVOQ replacing HUMIRA's lost revenue

The report's mention of Skyrizi growing 22.7% while Humira fell 31.2% confirms the exact transition the market has already priced into the stock.

What ABBV's price assumes · Sep 4

• healthcare▲8%
• guidance
• cash flow
• dividends
• ABBV
• BMY
• PFE
• debt
• patent cliff
• payout ratio